{"entity":{"id":"nct07683949","kind":"trial","name":"Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fl","aka":["LENCAP-CRC"],"tldr":"A phase 1/2 trial in colorectal cancer, run by Seoul National University Bundang Hospital, now recruiting.","summary":"Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidine is a phase 1/2, interventional study registered as NCT07683949 by Seoul National University Bundang Hospital, with a registry enrolment figure of 93 participants, started 2026-06-15 and due to reach its primary completion in 2029-10-31. Interventions recorded: Lenvanib (Lenvatinib),Xeloda (capecitabine). Conditions listed: Advanced Colorectal Cancer (Part 1). Primary outcome: Primary Efficacy Analysis. Colorectal eligibility wording from the registry: \"* 1\\) Voluntarily signed written informed consent 2) Male or female ≥19 years of age 3) Histologically confirmed metastatic or unresectable colorectal adenocarcinoma 4) Metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines 5) ECOG performance status 0, 1, or 2 6) \". Sites: South Korea. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07683949","url":"https://clinicaltrials.gov/study/NCT07683949"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07683949","phase":"1/2","setting":"A Phase I/II Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidine","sponsor":"Seoul National University Bundang Hospital","participation":[{"nct":"NCT07683949","source":"https://clinicaltrials.gov/study/NCT07683949","fetchedAt":"2026-10-07T16:55:56.330Z","studySha256":"887ecc1bf2a42dc267fa9dadaf25d7c5b51427e256757f571a9bf1cfc7186053","overallStatus":"ENROLLING_BY_INVITATION","lastUpdatePosted":"2026-07-06","leadSponsor":"Seoul National University Bundang Hospital","collaboratorCount":1,"minimumAge":"19 Years","maximumAge":"99 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":93,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["South Korea"]}],"started":"2026-06-15","startedType":"estimated","enrolled":93,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07683949/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}